The investment seeks daily investment results, before fees and expenses, of 300% of the daily performance of the S&P Biotechnology Select Industry Index ("index")... Show more
The Direxion Daily S&P Biotech Bull 3X Shares, trading under the ticker LABU, is a leveraged exchange-traded fund (ETF) that aims to deliver three times the daily performance of the S&P Biotechnology Select Industry Index. An ETF is a fund that trades on an exchange like a stock and holds a basket of assets. LABU stands out because of its aggressive, amplified exposure to one of the most volatile corners of the health care sector: biotechnology. Investors follow it as a high-powered tool for expressing short-term views on biotech stocks, but its leverage makes it unsuitable for many long-term portfolios.
LABU’s investment objective is straightforward but demanding: it seeks daily investment results, before fees and expenses, of 300% of the performance of the S&P Biotechnology Select Industry Index. To achieve this amplified exposure, the fund invests at least 80% of its assets in the securities that make up the underlying index and in financial instruments—most notably swap agreements—that provide leveraged exposure to that index. Swaps are contracts through which the fund can gain or lose exposure to the index’s returns without holding every underlying stock directly.
The fund is passively managed, meaning it tracks a rules-based index rather than relying on a portfolio manager’s stock selection. The S&P Biotechnology Select Industry Index is an equal-weighted benchmark composed of U.S.-listed biotechnology companies, spanning established names and smaller, clinical-stage developers alike. LABU is issued by Direxion, a firm known for its lineup of leveraged and inverse ETFs, and was launched on May 28, 2015.
LABU’s sector exposure is concentrated entirely within biotechnology and, more broadly, the health care industry. Its portfolio holdings typically include a large number of underlying biotech equities—often well over 100 names—alongside the swap contracts and short-term cash instruments used to generate the fund’s 3x leverage. Because the index is equal-weighted, no single stock dominates the portfolio; top underlying equity positions have historically included companies such as MRNA, REGN, VRTX, INSM, and NTRA, though these individual weights are generally modest.
The fund’s expense ratio—the annual fee deducted from fund assets—is approximately 0.96%, which is higher than typical unleveraged index ETFs and reflects the cost of maintaining the derivative exposure. Because the fund rebalances and resets its leverage daily, its composition and the mechanics of its swaps are adjusted continuously to keep the 300% target in place.
LABU attracts attention primarily as a vehicle for amplified, short-term bets on biotechnology. The biotech sector is known for sharp price swings driven by clinical trial results, regulatory decisions from the U.S. Food and Drug Administration (FDA), mergers and acquisitions (M&A), and broader risk sentiment toward high-growth health care names. LABU allows traders to magnify these moves—both upward and downward—on a daily basis without using a margin account or trading individual stocks.
For experienced traders, the fund offers a convenient way to gain concentrated leverage on a diversified basket of biotech companies in a single, liquid ticker. It can also serve as a tactical portfolio tool for expressing a short-term bullish view on the sector. However, its design makes it a poor fit for investors seeking long-term growth or steady income, since the daily reset mechanism causes its long-run returns to diverge meaningfully from a simple 3x multiple of the index.
LABU’s most significant risk is leverage combined with daily reset. While it targets 300% of the index’s return each day, compounding means its performance over weeks, months, or years can be drastically different from three times the index’s cumulative return—often to the downside in volatile or declining markets. This effect, sometimes called volatility decay, can erode value even when the underlying index is roughly flat.
Additional risks include sector concentration in biotechnology, which is inherently volatile and sensitive to clinical, regulatory, and funding developments; tracking error, or the gap between the fund’s actual performance and its stated objective; and the fund’s relatively high expense ratio. Leveraged ETFs are also generally intended to be held for no more than a single trading session, and holding them longer can produce outcomes that differ substantially from investor expectations. These characteristics make LABU suitable only for sophisticated traders who understand and actively monitor leveraged products.
Tickeron’s AI Screener is an AI-powered stock and ETF discovery platform that helps traders and investors identify opportunities using technical indicators, fundamentals, volatility, trends, AI-generated signals, industries, price patterns, and customizable filters. Users can efficiently screen thousands of stocks and ETFs to surface ideas that match their own investment strategies. Explore the AI Screener to build a watchlist tailored to your approach.
The Direxion Daily S&P Biotech Bull 3X Shares (LABU) occupies a distinctive niche in the ETF landscape: it offers aggressive, daily-reset leverage over the U.S. biotechnology sector in a single, liquid package. Its investment strategy and financial profile make it a powerful tactical instrument for experienced traders, while its concentration, leverage, and volatility risk make it unsuitable for most long-term investors. Understanding how its daily 3x objective works is essential before considering any position.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.